drugset / Trial / NCT03359005
Irinotecan and Temozolomide for Ewing Sarcoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators explored the activity of vincristine and irinotecan combined with temozolomide (VIT) in patients with relapsed and metastatic Ewing Sarcoma.
Timeline
- Start
- 2018-02-07
- Primary completion
- 2022-11-28
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Temozolomide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |